Use of Multiple CNS-Affecting Drugs Increasing Among Seniors

Share this content:
Use of Multiple CNS-Affecting Drugs Increasing Among Seniors
Use of Multiple CNS-Affecting Drugs Increasing Among Seniors

MONDAY, Feb. 13, 2017 (HealthDay News) -- There has been a sharp rise in the number of American seniors who take three or more medications that affect their central nervous system, according to a research letter published online Feb. 13 in JAMA Internal Medicine.

The study looked at seniors' use of antipsychotics, benzodiazepines, nonbenzodiazepine benzodiazepine receptor agonists, tricyclic antidepressants, selective serotonin reuptake inhibitors, and opioids. A review of U.S. Centers for Disease Control and Prevention data showed that the use of these drugs in people over 65 more than doubled from 2004 to 2013.

The researchers estimated that 3.68 million physician visits a year are by seniors taking three or more of these drugs. The largest increase was seen among seniors in rural areas. There, the use of these drugs more than tripled. Nearly half of seniors taking these drug combinations didn't have a formal diagnosis of a mental health condition, insomnia, or pain condition.

"The rise we saw in these data may reflect the increased willingness of seniors to seek help and accept medication for mental health conditions -- but it's also concerning because of the risks of combining these medications," lead author Donovan Maust, M.D., a geriatric psychiatrist at the University of Michigan's academic medical center in Ann Arbor, said in a university news release. "We hope that the newer prescribing guidelines for older adults encourage providers and patients to reconsider the potential risks and benefits from these combinations."

Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions

More in Home

FDA Approves Kinase Inhibitor for Treatment of AML

FDA Approves Kinase Inhibitor for Treatment of AML

Midostaurin, in combination with chemotherapy, treats acute myeloid leukemia in adults

Enzyme Replacement Drug OK'd for Form of Batten Disease

Enzyme Replacement Drug OK'd for Form of Batten ...

Brineura will be used to treat children with late infantile neuronal ceroid lipofuscinosis type 2 Batten

is free, fast, and customized just for you!

Already a member?

Sign In Now »